Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?
Günther Hochhaus, Mong‐Jen Chen, Abhinav Kurumaddali, Uta Schilling, Yuanyuan Jiao, Stefanie K. Drescher, Elham Amini, Simon M. Berger, Bhargava Kandala, Christine Tabulov, Jie Shao, Brandon Seay, Mutasim Abu‐Hasan, Sandra M. Baumstein, Lawrence H. Winner, Jagdeep Shur, Robert Price, Michael Hindle, Xiangyin Wei, Cynthia Carrasco, Dennis Sandell, Oluwamurewa Oguntimein, Minori Kinjo, Renishkumar Delvadia, Bhawana Saluja, Sau L. Lee, Denise S. Conti, Jürgen B. Bulitta
Topics & Concepts
Fluticasone propionateBioequivalenceDry-powder inhalerCmaxPharmacokineticsPharmacologyBronchodilatorInhalationCrossover studyChemistryFluticasoneMedicineInhalerChromatographyInternal medicineAnesthesiaPlaceboAsthmaAlternative medicinePathologyInhalation and Respiratory Drug DeliveryAsthma and respiratory diseasesDrug Solubulity and Delivery Systems